Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis
Laurent Eckert(Sanofi (France)), David M. Pariser(Eastern Virginia Medical School), Usha G. Mallya, Matt Reaney(Sanofi (United Kingdom)), T. Michelle Brown(RTI Health Solutions), Eric L. Simpson(Oregon Health & Science University), Min Yang(Analysis Group (United States)), Lauren Nelson(RTI Health Solutions), Isabelle Guillemin, Abhijit Gadkari(Regeneron (United States)), Puneet Mahajan(Research Triangle Park Foundation), Mark Boguniewicz(University of Colorado Denver)
Cited by 0
Related Papers
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
|New England Journal of Medicine|2014|1.4k
Guidelines of care for the management of atopic dermatitis
|Journal of the American Academy of Dermatology|2013|1.3k
Guidelines of care for the management of atopic dermatitis
|Journal of the American Academy of Dermatology|2014|1.2k
Cytokine modulation of atopic dermatitis filaggrin skin expression
|Journal of Allergy and Clinical Immunology|2007|1.1k